Last reviewed · How we verify
Glasdegib Supra-therapeutic Exposure — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Glasdegib Supra-therapeutic Exposure (Glasdegib Supra-therapeutic Exposure) — Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Glasdegib Supra-therapeutic Exposure TARGET | Glasdegib Supra-therapeutic Exposure | Pfizer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Glasdegib Supra-therapeutic Exposure CI watch — RSS
- Glasdegib Supra-therapeutic Exposure CI watch — Atom
- Glasdegib Supra-therapeutic Exposure CI watch — JSON
- Glasdegib Supra-therapeutic Exposure alone — RSS
Cite this brief
Drug Landscape (2026). Glasdegib Supra-therapeutic Exposure — Competitive Intelligence Brief. https://druglandscape.com/ci/glasdegib-supra-therapeutic-exposure. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab